Article
EGFR controls transcriptional and metabolic rewiring in KRASG12D colorectal cancer.
EMBO molecular medicine - 1 Jun 2025
Krauß Dana, Moreno-Viedma Veronica, Adachi-Fernandez Emi, de Sá Fernandes Cristiano, Genger Jakob-Wendelin, Fari Ourania, Blauensteiner Bernadette, Kirchhofer Dominik, Bradaric Nikolina, Gushchina Valeriya, Fotakis Georgios, Mohr Thomas, Abramovich Ifat, Mor Inbal, Holcmann Martin, Bergthaler Andreas, Haschemi Arvand, Trajanoski Zlatko, Winkler Juliane, Gottlieb Eyal, Sibilia Maria
Abstract excerpt
Inhibition of the epidermal growth factor receptor (EGFR) shows clinical benefit in metastatic colorectal cancer (CRC) patients, but KRAS-mutations are known to confer resistance. However, recent reports highlight EGFR as a crucial target to be co-inhibited with RAS inhibitors for effective treatment of KRAS mutant CRC. Here, we investigated the tumor cell-intrinsic contribution of EGFR in KRASG12D tumors by...
Topics
- Colorectal Neoplasms
- ErbB Receptors
- Animals
- Proto-Oncogene Proteins p21(ras)
- Humans
- Mice
- Organoids
- Mutation
- Gene Expression Regulation, Neoplastic